| abstract |
The present application relates to a conjugate comprising an amatoxin, a target-binding moiety wherein the target is CD20, <i>i.e</i>., a CD20-binding moiety, and optionally a linker linking said amatoxin and said CD20-binding moiety. The invention further relates to the synthesis of said conjugate. In addition, the invention relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of B-cell and/or lymphoma associated diseases and/or malignancies. |